Markets
Luke Kawa

S&P 500 closes at record high after late-day surge

The S&P 500 rose 0.2% to set fresh intraday and closing records, the Nasdaq 100 also advanced 0.2%, and the Russell 2000 outperformed with a 0.5% gain on Tuesday.

Commodity-linked S&P 500 sector ETFs (energy and materials) were the top-performing on the day, with tech, utilities, industrials, and financials also booking strong gains. Communication services were at the bottom of the leaderboard.

Chips performed well, buoyed by Micron and Intel, the latter of which boomed as acquisition rumors gained steam. Super Micro Computer’s ridiculously good month continued as investors keep buying into the story that its revenues will boom as Nvidia’s Blackwell sales ramp. The $3 trillion chip designer’s investment in WeRide also continues to fuel a massive surge in the Chinese self-driving car company’s shares.

Nike’s partnership with Kim Kardashian’s Skims produced the best day for the athletic giant since its former CEO abruptly announced his departure last September.

A filing released late Friday showed that Warren Buffett’s Berkshire Hathaway loaded up on Constellation Brands in the fourth quarter, sending shares higher.

Separately, BlackBerry got a big lift after a prominent hedge fund, Hood River, disclosed a significant stake in the cybersecurity company. Elsewhere in companies that have BB in their ticker and have seen better eras, Bath & Body Works soared on the heels of an upgrade from JPMorgan.

AMC gained as moviegoers the world over flocked to see the new “Captain America” movie despite poor reviews.

More Markets

See all Markets
markets

Tesla delivered 358,023 vehicles in Q1, short of expectations

Ahead of its first-quarter earnings later this month, Tesla on Thursday announced that it delivered 358,023 vehicles in the quarter.

Analysts polled by FactSet had expected 380,500 vehicle deliveries in the first quarter this year, while Tesla last month released its own company-compiled Wall Street consensus estimate — something it began in the fourth quarter of 2025 — of 365,645 vehicles.

Shares extended losses in premarket trading on Thursday, falling more than 4%.

The figure is still up from the same quarter last year, when Tesla delivered fewer than 337,000 vehicles amid intensifying competition in China and flailing public perception over CEO Elon Musk’s involvement with the Trump administration.

As of 3 p.m. ET on Wednesday, event contract odds held a slightly less optimistic view than the broader analyst community, but a sunnier view than the figure Tesla put forward. 52% of traders predicted Tesla’s Q1 deliveries would come in at more than 360,000, 40% thought the figure would be higher than 370,000, and 15% estimated it would be higher than 380,000.

(Event contracts are offered through Robinhood Derivatives, LLC — probabilities referenced or sourced from KalshiEx LLC or ForecastEx LLC.)

markets

Globalstar surges after FT reports that Amazon is in talks to buy the satellite group

Globalstar is up 11% in premarket trading on Thursday on reports that Amazon is in talks to buy the satellite company, in a push to take on Elon Musks SpaceX. The two companies are currently negotiating the details of a potential deal after lengthy talks, the Financial Times reported, citing people familiar with the matter.

Amazon has ambitions to compete with SpaceX to provide satellite-based internet access anywhere on the planet — a market thats dominated by Starlink at the moment and a key pillar of the eye-watering $1 trillion valuation that SpaceX is seeking in its IPO, which it has just confidentially filed for.

Indeed, Amazon has been signing deals with airlines and doubling down on investing in its internet constellation lately, with plans to increase its ~200 satellites in orbit to about 700 by the middle of 2026 — still a fraction compared to SpaceX’s mega constellation, which has some 10,000 active satellites.

But Amazon’s not the only Big Tech giant with an interest in Globalstar. Back in 2024, Apple invested $1.5 billion for a 20% stake in the company, necessitating a negotiation between Apple and Amazon for the latest deal talks to proceed, per the FT. SpaceX also reportedly had early talks with Globalstar, Bloomberg reported last October.

Globalstars stock has been up ~230% in the past year, pushing its value to some $8.8 billion as of yesterday’s close.

Amazon has ambitions to compete with SpaceX to provide satellite-based internet access anywhere on the planet — a market thats dominated by Starlink at the moment and a key pillar of the eye-watering $1 trillion valuation that SpaceX is seeking in its IPO, which it has just confidentially filed for.

Indeed, Amazon has been signing deals with airlines and doubling down on investing in its internet constellation lately, with plans to increase its ~200 satellites in orbit to about 700 by the middle of 2026 — still a fraction compared to SpaceX’s mega constellation, which has some 10,000 active satellites.

But Amazon’s not the only Big Tech giant with an interest in Globalstar. Back in 2024, Apple invested $1.5 billion for a 20% stake in the company, necessitating a negotiation between Apple and Amazon for the latest deal talks to proceed, per the FT. SpaceX also reportedly had early talks with Globalstar, Bloomberg reported last October.

Globalstars stock has been up ~230% in the past year, pushing its value to some $8.8 billion as of yesterday’s close.

markets

FDA clarifies stricter stance on GLP-1 compounding: Reuters

The Food and Drug Administration reiterated its increasingly strict stance on compounded versions of GLP-1s, Reuters reported Wednesday.

The FDA said that outside of drug shortages, “routine production” of copycat drugs is not allowed. Producing the compounded versions could now “prompt enforcement action,” Reuters reported.

Hims & Hers, which has historically been one of the largest sellers of copycat GLP-1s, fell more than 4% on Wednesday and slipped further in premarket trading on Thursday.

Hims attracted FDA scrutiny in February when it launched a copy of Novo Nordisk’s new GLP-1 pill. At the time, the FDA said it would take “decisive steps” to restrict GLP-1 compounding in a statement that specifically called out Hims.

After a bitter spat with Novo, which makes Ozempic and Wegovy, Hims entered a pact with the drugmaker in which it agreed not to market compounded GLP-1s.

Hims & Hers, which has historically been one of the largest sellers of copycat GLP-1s, fell more than 4% on Wednesday and slipped further in premarket trading on Thursday.

Hims attracted FDA scrutiny in February when it launched a copy of Novo Nordisk’s new GLP-1 pill. At the time, the FDA said it would take “decisive steps” to restrict GLP-1 compounding in a statement that specifically called out Hims.

After a bitter spat with Novo, which makes Ozempic and Wegovy, Hims entered a pact with the drugmaker in which it agreed not to market compounded GLP-1s.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.